{"id":"W3039580871","doi":"10.1016/j.ygyno.2020.06.493","title":"Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study","year":2020,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":78,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"National Cancer Institute; AstraZeneca; Genentech; Bristol-Myers Squibb Canada; AbbVie; Eli Lilly and Company","keywords":"Medicine; Gynecologic oncology; Internal medicine; Cervical cancer; Progression-free survival; Oncology; Bevacizumab; Population; Adverse effect; Phases of clinical research; Stage (stratigraphy); Chemotherapy; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009507975,0.001337722,0.001432088,0.0004734654,0.0004326193,0.001114808,0.0008872122,0.001320346,0.004908437],"category_scores_gemma":[0.0004255812,0.000536317,0.001285492,0.0004136708,0.0008845183,0.0007899379,0.0003399899,0.002529607,0.001170039],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008841471,"about_ca_system_score_gemma":0.001359537,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002289466,"about_ca_topic_score_gemma":0.004638228,"domain_scores_codex":[0.9997585,0.00009546896,0.000007476295,0.00004648856,0.00002024742,0.00007169174],"domain_scores_gemma":[0.999635,0.00004417556,0.000049743,0.00004114031,0.00002107151,0.0002088602],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6469913,0.101287,0.008091872,0.0009921179,0.002169312,0.0003328269,0.0005016029,0.004720483,0.08501428,0.0007616256,0.006020504,0.1431171],"study_design_scores_gemma":[0.4481048,0.5253149,0.01228064,0.00004184075,0.0008351352,0.0002425073,0.000157769,0.001332003,0.006061354,0.0003314293,0.005264724,0.00003280747],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920102,0.001851989,0.0005719119,0.000445323,0.0001492693,0.001807607,0.001132099,0.00009738467,0.001934349],"genre_scores_gemma":[0.9857976,0.002778769,0.001246385,0.0007223244,0.0001398331,0.00152634,0.002404093,0.00004633237,0.005338262],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004908437,"threshold_uncertainty_score":0.01642036,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06016707646096833,"score_gpt":0.3463446853480107,"score_spread":0.2861776088870424,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}